Article

Generic Zomig and Vfend Launched by Ajanta Pharma

Author(s):

Ajanta Pharma Limited has been given final approval from the FDA to launch zolmitriptan tablets, 2.5 mg and 5 mg, and voriconazole tablets, 50 mg and 200 mg.

Ajanta Pharma Limited has been given final approval from the FDA to launch zolmitriptan tablets, 2.5 mg and 5 mg, and voriconazole tablets, 50 mg and 200 mg.

The zolmitriptan tablets may be used for the acute treatment of migraines, and it is the bioequivalent generic version of Zomig, which is marketed by Impax Pharmaceuticals.

The most common adverse effects associated with zolmitriptan include nausea, pain, tingling sensation, and unusual taste. However, some individuals may also have an increased risk of heart attacks, high blood pressure, and stroke.

Two days after the approval of the zolmitriptan tablets, Ajanta announced that it had also received FDA approval for its voriconazole tablets, which are a generic version of Pfizer’s Vfend. Patients can use Ajanta’s generic version to treat serious invasive fungal infections.

Visual disturbances, fever, nausea, rash, vomiting, chills, headache, tachycardia, and hallucinations are some of the potential adverse effects associated with voriconazole.

To date, the FDA has granted 9 abbreviated new drug application final approvals and 2 tentative approvals to Ajanta Pharma Limited.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit: Sebastian Kaulitzki | stock.adobe.com
Health and nutrition: the role of glp-1 in diabetes management with apple and syringe - Image credit: Thanayut | stock.adobe.com
Image credit: K KStock | stock.adobe.com
Image credit: komokvm | stock.adobe.com
Vial of Pneumococcal vaccine - Image credit: Bernard Chantal | stock.adobe.com
Vaccine vials used for Respiratory Syncytial Virus (RSV) with a syringe - Image credit:  Peter Hansen | stock.adobe.com